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Article
The global burden of scabies: a cross-sectional analysis from 
the Global Burden of Disease Study 2015
Chante Karimkhani, Danny V Colombara, Aaron M Drucker, Scott A Norton, Roderick Hay, Daniel Engelman, Andrew Steer, Margot Whitfeld, 
Mohsen Naghavi, Robert P Dellavalle
Summary
Background Numerous population-based studies have documented high prevalence of scabies in overcrowded 
settings, particularly among children and in tropical regions. We provide an estimate of the global burden of scabies 
using data from the Global Burden of Disease (GBD) Study 2015.
Methods We identified scabies epidemiological data sources from an extensive literature search and hospital insurance 
data and analysed data sources with a Bayesian meta-regression modelling tool, DisMod-MR 2·1, to yield prevalence 
estimates. We combined prevalence estimates with a disability weight, measuring disfigurement, itch, and pain 
caused by scabies, to produce years lived with disability (YLDs). With an assumed zero mortality from scabies, YLDs 
were equivalent to disability-adjusted life-years (DALYs). We estimated DALYs for 195 countries divided into 21 world 
regions, in both sexes and 20 age groups, between 1990 and 2015.
Findings Scabies was responsible for 0·21% of DALYs from all conditions studied by GBD 2015 worldwide. 
The world regions of east Asia (age-standardised DALYs 136·32), southeast Asia (134·57), Oceania (120·34), 
tropical Latin America (99·94), and south Asia (69·41) had the greatest burden of DALYs from scabies. 
Mean percent change of DALY rate from 1990 to 2015 was less than 8% in all world regions, except North America, 
which had a 23·9% increase. The five individual countries with greatest scabies burden were Indonesia 
(age-standardised DALYs 153·86), China (138·25), Timor-Leste (136·67), Vanuatu (131·59), and Fiji (130·91). The 
largest standard deviations of age-standardised DALYs between the 20 age groups were observed in southeast 
Asia (60·1), Oceania (58·3), and east Asia (56·5), with the greatest DALY burdens in children, adolescents, and 
the elderly.
Interpretation The burden of scabies is greater in tropical regions, especially in children, adolescents, and elderly 
people. As a worldwide epidemiological assessment, GBD 2015 provides broad and frequently updated measures of 
scabies burden in terms of skin effects. These global data might help guide research protocols and prioritisation 
efforts and focus scabies treatment and control measures.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Scabies is a skin infestation caused by the mite 
Sarcoptes scabiei that causes a pruritic skin eruption.1 
Given that scabies transmission occurs with person-to-
person contact, scabies is particularly prevalent in 
resource-poor conditions and among children, and is 
associated with insufficient access to health-care 
subsidies. Scabies can occur in any setting but over the 
past century has become less prevalent in temperate 
regions and is more common in tropical, humid regions. 
The predominant symptom of scabies infestation is 
pruritus, which can be debilitating. Disruption of the 
skin’s protective barrier function promotes secondary 
bacterial infections, which can lead to additional, 
potentially life-threatening, complications.2
Scabies has high prevalence in the tropics and large 
cumulative morbidity. Recognition of scabies on the 
global health agenda would increase awareness, 
education, and research into diagnosis, treatment, and 
prevention.3 In recognition, WHO recently formally 
designated scabies as a neglected tropical disease.4 
Previous investigations have reported on scabies 
prevalence in specific, often low-resource, communities.5–8 
A systematic review of 48 population-based studies found 
the highest prevalence of scabies in Papua New Guinea, 
Panama, and Fiji.9 However, beyond prevalence, the 
extent to which scabies affects these communities is 
unknown. In this paper, we provide estimates for the 
global burden of scabies skin disease using data from the 
Global Burden of Disease (GBD) study.
GBD provides a way to measure and compare health 
loss from disease and injury across age, sex, location, and 
time.10 GBD is based on formal, systematic, and 
statistically rigorous analyses of effects of disease and 
injuries on the health of populations. As an international 
collaboration of more than 500 experts representing 
30 countries, GBD 2015, the third iteration of the GBD 
process, quantified the effects of 315 diseases and 
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injuries, including scabies, in 195 countries from 
1990 to 2015.11 Disease burden is measured using the 
disability-adjusted life-years (DALYs) metric, which 
uniquely combines mortality (estimated using years of 
life lost [YLL]) and morbidity (estimated using years lived 
with disability [YLD]) components. By assessing disease 
epidemiology on a global scale, GBD has the potential to 
inform health policy and identify previously undervalued 
or neglected conditions, such as scabies. The DALY 
metric has broad clinical and research priority-setting 
implications because it assesses both the prevalence and 
impact of a disease and allows for comparison of various 
diseases. This report presents GBD 2015 results on the 
global burden of scabies.
Methods
Data collection
Although details of GBD methods are extensively 
published elsewhere,11–13 a brief overview specific to 
scabies is presented here. The GBD category of scabies 
is defined by the International Classification of Diseases 
(ICD)-9 code 133 and ICD-10 code B86. A systematic 
literature search was done and results were screened by 
title and abstract to identify relevant studies, which then 
underwent full-text screening and data extraction. 
Studies published between 1980–2014 that provided data 
on scabies incidence or prevalence, used samples 
representative of the general population that were larger 
than 100, and provided sufficient information on 
methods to assess study quality as well as rules for 
extracting uncertainty (standard error and 95% CI) were 
included. Additionally, US health insurance claims data 
from 2000, 2010, and 2012 were included (appendix). 
38 studies on scabies prevalence in 84 countries and 
three studies on scabies incidence in five countries were 
included. All extracted scabies incidence and prevalence 
datapoints were age-sex split and adjusted from primary 
code to all code based on the claims data. These 
datapoints were then input into DisMod-MR 2.1, a 
Bayesian meta-regression tool, which estimates scabies 
prevalence by location, year, age, and sex. For the 
DisMod-MR 2.1 analysis, scabies was modelled with 
remission set between 1 and 9, corresponding to 
durations of 6 weeks to 1 year, and mortality was assumed 
to be zero, on the basis of available epidemiological data, 
expert opinion, and previous GBD studies. As a proxy for 
low levels of development, improved water source 
(proportion of population with access to sufficient 
quantities of  water) was used as a country-level covariate. 
For countries or regions with missing data, DisMod-MR 
2.1 uses data in nearby countries, regions, and predictive 
covariates to estimate data.
GBD divides disease prevalence into varying severity 
levels. Scabies prevalence was categorised as one severity 
level: disfigurement level 1 with itch or pain. This severity 
level corresponded to the lay description: “The individual 
has a slight visible physical deformity that is sometimes 
sore or itchy. Observers notice the deformity, which 
causes some worry and discomfort to the patient”. 
The severity level was assigned on the basis of 
recommendations from the GBD 2010 Skin Conditions 
Expert Group.14 The severity prevalence estimates were 
multiplied with a disability weight to generate YLDs for 
each age-sex-country-year group. Disability weights, 
which range from 0 (least disabling) to 1 (most disabling), 
assessed the degree of disfigurement with itch or pain 
from scabies in four population-based European surveys 
and an open-access web-based survey of more than 
60 890 respondents.15 The disability weight assigned to 
scabies was 0·027 (95% CI 0·015–0·042). Notably, this 
weighting only takes into account the effect of scabies on 
the skin.
With scabies, YLL is assumed to be zero; YLDs were 
equivalent to DALYs. DALY metrics are computed as 
age-standardised and age-specific DALY rate per 
100 000 persons and mean percent change in 
Research in context
Evidence before this study
We searched PubMed and Google Scholar databases on 
July 15, 2017, for articles in English, Spanish, and French published 
before June 30, 2017, using the key word “scabies” in the title or 
abstract. Studies reported high-risk population-based national 
and subnational estimates of scabies prevalence as well as 
associated comorbidities such as psychological disorders. 
However, previous attempts to estimate the global burden of 
scabies skin infection were not available. The Global Burden of 
Disease (GBD) Study 2015 assesses scabies epidemiological data 
sources from a PubMed and Google Scholar literature search in 
English and Spanish between 1980 and 2014. Prevalence and 
incidence metrics were extracted from included sources and 
analysed with a Bayesian meta-regression modelling tool. Burden 
of disease is estimated as disability-adjusted life-years (DALYs).
Added value of this study
This study is the first global effort to measure the burden of 
scabies. The greatest DALYs from scabies are in tropical 
regions in east Asia, southeast Asia, Oceania, tropical 
Latin America, and south Asia, especially in children, 
adolescents, and the elderly.
Implications of all the available evidence
Increased global awareness of the burden from scabies will 
promote international efforts for control of this preventable 
disease. GBD provides high-quality estimates, which can be 
used to set research priorities, promote discussion, and 
ultimately, enact change, at local, national, and global 
stages.
See Online for appendix
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age-standardised DALY rate from 1990–2015. Scabies 
estimates are made for both sexes, 20 age groups 
(ranging from 0 days to >80 years), and 21 world regions 
that include 195 countries and territories (panel). 
Age-standardisation was based on GBD 2013 estimates 
of the standard population structure from 2010–35 
based on the most recent World Population Prospects 
publication by the UN Population Division.16 To assess 
variance of DALYs by age for a particular region, 
standard deviation in each of the 20 age groups was 
calculated. DALY metrics were organised and analysed 
in Microsoft Excel, version 14.7.1. The Global Burden 
of Disease Study is approved by the international 
review board of the University of Washington until 
March 25, 2018.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The GBD 2015 global prevalence of scabies in both sexes 
was 204 151 715 (95% CI 177 533 726–237 466 220).13 
Scabies caused 0·21% of DALYs from all conditions 
studied by GBD 2015 globally. Global age-standardised 
DALYs per 100 000 people from scabies was 71·11 (95% CI 
39·77–116·03) for both sexes,11 and 70·58 (39·79–114·37) 
for men and 71·72 (39·90–117·83) for women (data not 
Panel: Global Burden of Disease regions and countries within each region
East Asia
China, North Korea, and Taiwan (province of China)
Oceania
American Samoa, Federated States of Micronesia, Fiji, Guam, 
Marshall Islands, Northern Mariana Islands, Papua New Guinea, 
Samoa, Solomon Islands, Tonga, and Vanuatu
Southeast Asia
Cambodia, Indonesia, Laos, Malaysia, Maldives, Mauritius, 
Myanmar, Philippines, Sri Lanka, Seychelles, Thailand, 
Timor-Leste, and Vietnam
South Asia
Bangladesh, Bhutan, India, Nepal, and Pakistan
Central Asia
Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, 
Mongolia, Tajikistan, Turkmenistan, and Uzbekistan
Central Europe
Albania, Bosnia and Herzegovina, Bulgaria, Croatia, 
Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, 
Slovakia, and Slovenia
Eastern Europe
Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, and Ukraine
North Africa and Middle East
Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, 
Lebanon, Libya, Morocco, Palestine, Oman, Qatar, Saudi Arabia, 
Sudan, Syria, Tunisia, Turkey, United Arab Emirates, and Yemen
Western sub-Saharan Africa
Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Côte d’Ivoire, 
The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, 
Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, 
Sierra Leone, and Togo
Southern sub-Saharan Africa
Botswana, Lesotho, Namibia, South Africa, Swaziland, and 
Zimbabwe
Eastern sub-Saharan Africa
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, 
Malawi, Mozambique, Rwanda, Somalia, South Sudan, Tanzania, 
Uganda, and Zambia
Central sub-Saharan Africa
Angola, Central African Republic, Congo (Brazzaville), Democratic 
Republic of the Congo, Equatorial Guinea, and Gabon
Tropical Latin America
Brazil and Paraguay
Andean Latin America
Bolivia, Ecuador, and Peru
Central Latin America
Colombia, Costa Rica, El Salvador, Guatemala, Honduras, 
Mexico, Nicaragua, Panama, and Venezuela
Caribbean
Antigua and Barbuda, The Bahamas, Barbados, Belize, Bermuda, 
Cuba, Dominica, Dominican Republic, Grenada, Guyana, Haiti, 
Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the 
Grenadines, Suriname, Trinidad and Tobago, and Virgin Islands
Western Europe
Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, 
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, 
Malta, Netherlands, Norway, Portugal, Spain, Sweden, 
Switzerland, and UK
Southern Latin America
Argentina, Chile, and Uruguay
North America
Canada, Greenland, and USA
Asia Pacific
Brunei, Japan, Singapore, and South Korea
Australasia
Australia and New Zealand
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shown). Of 246 conditions comparatively ranked by GBD 
2015, scabies ranked 101 in age-standardised global 
DALYs, after adverse effects of medical treatment 
(ranked 98), viral skin diseases (99), and 
Haemophilus influenzae type b meningitis (100), and 
before atrial fibrillation or flutter (102), acute lymphoid 
leukaemia (103), and other transport injuries (104). 
Global age-standardised DALYs in 20 age groups are 
shown in table 1.
The five world regions with the greatest age-standardised 
DALY burdens caused by scabies in decreasing order were 
east Asia 136·32 (95% CI 75·83–222·35), southeast Asia 
134·57 (74·62–223·64), Oceania 120·34 (68·10–194·84), 
tropical Latin America 99·94 (56·75–163·50), and south 
Asia 69·41 (39·73–112·65; figure 1). Mean percent changes 
in age-standardised DALYs from 1990 to 2015 range from 
21·87% (97·5% uncertainty interval [UI] 10·83 to 37·36) 
in North America to –7·92% (–10·07 to –5·51) in eastern 
sub-Saharan Africa (table 2). The regions with greatest 
standard deviation of DALY burdens of the 20 age groups 
were southeast Asia 60·1, Oceania 58·3, and east 
Asia 56·5 (figure 2). The regions with the lowest standard 
deviation of DALY burden of the 20 age groups were 
Asia Pacific 2·2, North America 1·8, and western 
Europe 0·6.
Of the 195 countries analysed, the ten countries 
with the highest age-standardised scabies DALY 
burdens per 100 000 people were Indonesia 153·86 
(95% CI 86·48–254·02), China 138·25 (76·96–225·56), 
Timor-Leste 136·67 (77·18–221·37), Vanuatu 131·59 
(72·56–214·30), Fiji 130·91 (73·01–211·81), Cambodia 
126·93 (70·61–214·55), Laos 124·96 (69·32–210·08), 
Global DALYs per 100 000 people (95% CI)
0–6 days 2·35 (1·20–4·00)
7–27 days 10·97 (5·56–18·81)
28–364 days 73·72 (37·33–125·03)
1–4 years 116·30 (59·28–205·71)
5–9 years 99·25 (48·95–183·04)
10–14 years 95·22 (46·24–164·65)
15–19 years 101·88 (50·78–177·68)
20–24 years 96·76 (46·15–176·88)
25–29 years 73·28 (35·03–141·91)
30–34 years 53·20 (26·13–96·12)
35–39 years 47·66 (23·14–86·20)
40–44 years 50·24 (23·54–89·20)
45–49 years 49·94 (24·52–92·29)
50–54 years 44·63 (21·98–83·38)
55–59 years 39·94 (19·31–69·18)
60–64 years 38·80 (19·51–67·56)
65–69 years 40·02 (20·31–71·07)
70–74 years 42·80 (21·40–76·67)
75–79 years 52·34 (25·26–92·46)
≥80 years 46·38 (24·03–78·30)
DALYs=disability-adjusted life-years.
Table 1: Global DALYs from scabies skin infection by age
Figure 1: Global 2015 scabies age-standardised DALYs per 100 000 people in males, females, and both sexes
DALYs=disability-adjusted life-years.
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Myanmar 124·46 (68·50–208·53), Vietnam 123·30 
(68·41–207·56), and Seychelles 122·99 (67·38–203·58; 
figure 3).
Discussion
Our analysis of GBD 2015 shows that the greatest burden 
from scabies is in countries in east Asia, southeast Asia, 
Oceania, and tropical Latin America. This is supported 
by previous prevalence studies, which have reported high 
prevalence of scabies in hot, tropical areas where 
overcrowding facilitates the rapid spread of the scabies 
mite.5–9 The burden of scabies over the human lifespan 
has differing patterns in regions with high or low scabies 
burden. In east and southeast Asia, the regions with 
greatest scabies burden, DALY burden is highest in 
children aged 1–4 years, followed by a high but gradually 
decreasing burden from age 5 to 24 years. DALY burdens 
decrease substantially during adulthood, before 
increasing slightly after the age of 70 years. This pattern 
is much less pronounced in North America and western 
Europe, which are the regions with the lowest overall 
scabies burdens. In these low-burden regions, scabies 
prevalence is more evenly distributed across all age 
groups, including elderly people, in whom outbreaks of 
infestations have occurred in care homes.17,18
When comparing scabies burden by sex, most world 
regions had an even distribution between males and 
females. The greatest discrepancies were in eastern 
Europe and central Europe, where the ratios of 
Mean percent change in 
DALYs 1990–2015 (97·5% UI)
Global –5·38 (–7·81 to –3·14)
North America 23·87 (10·83 to 37·36)
Southern Latin America 0·69 (–5·38 to –6·99)
Western Europe 0·32 (–4·57 to 5·46)
Australasia 0·02 (–4·97 to 5·22)
Central Europe 0·06 (–2·64 to 2·32)
Asia Pacific –0·29 (–4·21 to 4·22)
Eastern Europe –0·83 (–4·78 to 3·83)
Caribbean –0·84 (–3·75 to 1·80)
South Asia –1·12 (–5·23 to 3·17)
Central Latin America –1·30 (–3·83 to 2·33)
Andean Latin America –1·51 (–5·34 to 2·54)
Southern sub-Saharan Africa –1·54 (–5·58 to 2·75)
Central Asia –1·79 (–4·69 to 1·00)
Tropical Latin America –2·55 (–7·21 to 2·26)
Central sub-Saharan Africa –2·62 (–6·89 to 2·19)
Southeast Asia –2·66 (–6·15 to 1·02)
North Africa and Middle East –2·86 (–5·17 to –0·09)
East Asia –3·18 (–7·71 to 1·76)
Western sub-Saharan Africa –7·16 (–10·25 to –3·45)
Oceania –7·12 (–10·80 to –3·04)
Eastern sub-Saharan Africa –7·92 (–10·07 to –5·51)
Data are for both sexes from 1990 to 2015 globally and by world region. 
UI=uncertainty interval. DALYs=disability-adjusted life-years.
Table 2: Mean percent change in age-standardised DALYs
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Figure 2: Scabies DALYs per 
100 000 people by age and 
world region
DALYs=disability-adjusted life-
years.
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age-standardised DALYs in males to females were 1·23 
(eastern Europe) and 0·77 (central Europe). With the 
exception of North America, age-standardised DALY 
burdens from 1990 to 2015 across all 21 world regions did 
not change by more than 8%. North America had the 
largest mean percent change in age-standardised DALYs 
from 1990 to 2015, with an increase of 23·8%.
Although beyond the scope of this GBD analysis, 
subnational differences in the burden of scabies have 
previously been identified. For example, Aboriginal 
Australian communities have much higher prevalence 
of scabies than the non-indigenous population.19 
Several subnational regions within Ethiopia have been 
particularly affected by natural disasters such as the 
El Niño weather phenomenon, leading to severe drought 
and scabies outbreaks.20 Additionally, conflicts in areas 
such as Africa and the Middle East have led to increasing 
numbers of refugees seeking asylum in Europe. A recent 
investigation of a tertiary care hospital in Switzerland 
found high incidence of co-infection of multiple 
infectious diseases with scabies in African refugees.21
The potential impact of high-quality big data on health 
and disease is enormous. As the world becomes 
increasingly globalised, more and more attention is paid 
to diseases that disproportionately affect vulnerable 
populations. Although still highly neglected, renewed 
efforts are now directed toward the global control 
of scabies. The International Alliance for the Control of 
Scabies is a global network committed to the control of 
human scabies and the promotion of health and 
wellbeing of all those living in affected communities.22 
The availability of high-quality data on scabies burden, 
such as those provided by GBD 2015, is needed to enact 
local, national, and global change.
Funding bodies often consider diseases that dis-
proportionately affect particular populations in  their 
allocation of the limited financial resources. Research 
interest has recently increased in scabies diagnosis 
and treatment, and population-based interventions. A 
particularly notable area that warrants further research 
and implementation is mass drug administration 
(MDA) for community-wide control of scabies. A recent 
comparative study done on several Fijian islands over 
12 months showed superior effectiveness of oral 
ivermectin MDA over topical permethrin in the reduction 
of scabies prevalence.23
Figure 3: World map of scabies age-standardised disability-adjusted life-years per 100 000 people
ATG=Antigua and Barbuda. BRB=Barbados. COM=Comoros. DMA=Dominica. FJI=Fiji. FSM=Federated States of Micronesia. GRD=Grenada. KIR=Kiribati. LCA=Saint Lucia. MDV=Maldives. 
MHL=Marshall Islands. MLT=Malta. MUS=Mauritius. SGP=Singapore. SLB=Solomon Islands. SYC=Seychelles. TLS=Timor-Leste. TON=Tonga. TTO=Trinidad and Tobago. VCT=Saint Vincent and the 
Grenadines. VUT=Vanuatu. WSM=Samoa.
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The GBD 2015 scabies estimates have some limitations. 
One notable consideration is the fact that the GBD 
analysis data on secondary bacterial infection due to 
Streptococcus pyogenes and Staphylococcus aureus, which is 
causally related to the presence of the scabies mite, are not 
included. Complications of scabies such as impetigo, local 
and systemic bacterial infections, glomerulonephritis, and 
rheumatic fever are also not covered. Data from Fiji 
showed that the attributable risk of scabies infection on 
impetigo was 94%.5 Additionally, the variant of crusted 
scabies, which has very high mortality, is not considered 
by GBD. Thus, the GBD assumption that scabies has no 
mortality (YLL) estimation is entirely focused on the direct 
skin infection of this condition.
Another crucial deficit is poor case ascertainment in 
low-resource settings where scabies is most prevalent, 
including patient presentation, proper disease diagnosis, 
and adequate coding of scabies. For regions that have 
missing data, estimates are derived from data in nearby 
countries, regions, and predictive covariates. As an 
example, since there are no data sources on scabies 
epidemiology for sub-Saharan Africa, the estimates for 
this region are based on global estimates and the 
covariate of improved water source. The included scabies 
data sources used in GBD 2015 include US claims 
reports; however, the USA has a low scabies burden that 
might have distorted overall global results.
The GBD literature search was done only using 
PubMed and Google Scholar databases because of time 
and resource constraints. Thus, regional database 
searches were not done and the literature search was 
limited to English and Spanish languages. Since the 
GBD scabies method does not easily account for 
outbreaks or particular subgroups (other than age, sex, 
and geography), certain high-risk groups (eg, homeless 
populations in the USA) would slightly raise the overall 
scabies burden estimate for the larger population of 
which they are a part. The GBD disability weight method 
is founded on the principle that no disability double-
counting occurs. Thus, although the skin effects of 
scabies can cause more notable morbidity such as sleep 
deprivation, mental disorders, and renal problems than 
all other skin conditions, the disability weight for scabies 
assesses only the direct effect of skin infection and the 
GBD 2010 Skin Conditions Expert Group assigned it the 
severity of disfigurement level 1. A final limitation is that 
GBD modelling does not take into account various 
diagnostic methods such as different case definitions 
that might affect diagnosis estimates.
Scabies burden is greatest in tropical regions within east 
Asia, southeast Asia, Oceania, and tropical Latin America, 
especially in children, adolescents, and the elderly. 
Although similar global epidemiological studies are 
scarce, our findings agree with the systematic reviews and 
population-level and country-level investigations that we 
found.5–9 GBD 2015 allows for a high-quality, objective 
measure of scabies burden with regards to its effects on 
the skin. The premise of GBD is that every human being 
deserves to live a long life in full health, as described by 
the IHME. Scabies is an impediment to that goal, 
particularly in countries with high prevalence and poor 
access to effective treatment.
Of particular concern is the consistency of the DALY 
burden from scabies over the past 25 years from 
1990 to 2015. In most world regions, no change indicates 
that scabies burden remains low. However, no change in 
high-burden regions such as east Asia, southeast Asia, 
Oceania, and tropical Latin America might indicate 
inadequate treatment and control measures. Disease 
treatment and control is particularly difficult, because 
economically disadvantaged populations are prone to 
overcrowding and are less likely to afford proper 
medications or seek appropriate medical attention. Recent 
studies suggest that MDA campaigns hold the greatest 
benefit for these regions.
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